N-methyl-2-(1'-homopiperidinyl)ethylamine | 118808-13-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂环庚烷
• 英文名称: N-methyl-2-(1'-homopiperidinyl)ethylamine
• 英文别名: 2-(Azepan-1-yl)-N-methylethanamine
• CAS: 118808-13-2
• 化学式: C₉H₂₀N₂
• mdl: MFCD09034970
• 分子量: 156.271
• InChiKey: PCSDSPLJOYHMEW-UHFFFAOYSA-N

物化性质

• 沸点：
  211.7±8.0 °C(Predicted)
• 密度：
  0.877±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-methyl-2-(1'-homopiperidinyl)ethylamine 在 aluminium hydride 、 N,N'-二环己基碳二亚胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 0.58h， 生成 LR 172
  参考文献：
  名称：

  一类新型的N-（芳基乙基）-N-烷基-2-（1-吡咯烷基）乙胺的合成，表征和生物学评估：结构要求和对sigma受体的结合亲和力。

  摘要：

  通过合成和测试零件结构，N- [2-（3,4-二氯苯基）乙基] -N-甲基-2-（1-吡咯烷基）乙基胺（3）源自我们先前报道的高亲和力σ受体配体（1S，2R）-（-）-N- [2-（3,4-二氯苯基）-乙基] -N-甲基-2-（1-吡咯烷基）环己胺[（-）-2]和（+）-参见图2，我们已经鉴定出一类新型的对[3H]-（+）-3-PPP标记的σ受体具有特异性的超强（亚纳摩尔亲和力）σ配体。测试3从豚鼠脑膜置换[3H]-（+）-3-PPP的能力时，其Ki值为0.34 nM，优于其母体化合物（-）-2（Ki = 1.3 nM）和（+）-2（Ki = 6.0 nM）。与3相关的其他化合物，例如N- [2-（3,4-二氯苯基）乙基] -N-甲基-2-（1-高哌啶基）乙胺（19）的Ki = 0.17 nM [（3H]-（+ ）-3-PPP）。通过以多种不同方式操纵该结构来检查3的高sigma受体亲和力

  DOI：

  10.1021/jm00079a004
• 作为产物：
  描述：

  环己亚胺 在 lithium aluminium tetrahydride 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 7.0h， 生成 N-methyl-2-(1'-homopiperidinyl)ethylamine
  参考文献：
  名称：

  一类新型的N-（芳基乙基）-N-烷基-2-（1-吡咯烷基）乙胺的合成，表征和生物学评估：结构要求和对sigma受体的结合亲和力。

  摘要：

  通过合成和测试零件结构，N- [2-（3,4-二氯苯基）乙基] -N-甲基-2-（1-吡咯烷基）乙基胺（3）源自我们先前报道的高亲和力σ受体配体（1S，2R）-（-）-N- [2-（3,4-二氯苯基）-乙基] -N-甲基-2-（1-吡咯烷基）环己胺[（-）-2]和（+）-参见图2，我们已经鉴定出一类新型的对[3H]-（+）-3-PPP标记的σ受体具有特异性的超强（亚纳摩尔亲和力）σ配体。测试3从豚鼠脑膜置换[3H]-（+）-3-PPP的能力时，其Ki值为0.34 nM，优于其母体化合物（-）-2（Ki = 1.3 nM）和（+）-2（Ki = 6.0 nM）。与3相关的其他化合物，例如N- [2-（3,4-二氯苯基）乙基] -N-甲基-2-（1-高哌啶基）乙胺（19）的Ki = 0.17 nM [（3H]-（+ ）-3-PPP）。通过以多种不同方式操纵该结构来检查3的高sigma受体亲和力

  DOI：

  10.1021/jm00079a004

文献信息

• Asymmetric synthesis catalyzed by chiral ferrocenylphosphine transition metal complexes. 10 gold(i)-catalyzed asymmetric aldol reaction of isocyanoacetate
  作者：Tamio Hayashi、Masaya Sawamura、Yoshihiko Ito

  DOI：10.1016/s0040-4020(01)88870-0

  日期：1992.1

  Optically active ferrocenylbisphosphine ligands containing 2-(dialkylamino)ethylamino group on the ferrocenylmethyl position have been prepared and used for the gold(I)-catalyzed asymmetric aldol reaction of isocyanoacetate with aldehydes. Six-membered ring amines, such as morpholino or piperidino group, at the terminal of the side chain were most stereoselective to give optically active trans-4-

  制备了在二茂铁基甲基位置上含有2-（二烷基氨基）乙基氨基的旋光二茂铁基双膦配体，并将其用于金（I）催化的异氰基乙酸酯与醛的不对称醛醇缩合反应。侧链末端的六元环胺（例如吗啉代或哌啶子基）具有最高的立体选择性，可生成具有高对映体的光学活性反式-4-甲氧羰基-5-烷基-2-恶唑啉（ee最高可达97％） -和非对映选择性的定量收率。
• CARBAMOYL-SUBSTITUTED SPIRO DERIVATIVE
  申请人：BANYU PHARMACEUTICAL CO., LTD.

  公开号：EP1795527A1

  公开（公告）日：2007-06-13

  A compound represented by, e.g. the formula (I): [wherein X, Y, Z, and W each independently represent optionally substituted methine; A, B, and D each independently represent -C(O)-, etc.; Q represents a methine or a nitrogen; and R represents the formula (II-1), optionally substituted with lower alkyl, etc.; (wherein R6 represents a lower alkyl, etc; and R7 and R8 each independently represents a lower alkyl, etc.)] or a pharmaceutically acceptable salt of the compound. The compounds and salt have antagonistic activity against a histamine H3 receptor or inverse agonistic activity against a histamine H3 receptor. They are useful in the prevention or treatment of metabolic diseases, circulatory diseases, or neurotic diseases.

  如式(I)所代表的化合物： [其中 X、Y、Z 和 W 各自独立地代表任选取代的甲烷；A、B 和 D 各自独立地代表-C(O)-等；Q 代表甲烷或氮；R 代表式（II-1），任选被低级烷基等取代； (其中 R6 代表低级烷基等；R7 和 R8 各自独立地代表低级烷基等）]或该化合物的药学上可接受的盐。这些化合物和盐对组胺 H3 受体具有拮抗活性，或对组胺 H3 受体具有反向激动活性。它们可用于预防或治疗代谢性疾病、循环系统疾病或神经性疾病。
• Substituted Halogenated Arylsulfonamides:  A New Class of σ Receptor Binding Tumor Imaging Agents
  作者：Christy S. John、Benjamin B. Lim、Bertold J. Vilner、Brian C. Geyer、Wayne D. Bowen

  DOI：10.1021/jm9800447

  日期：1998.7.1

  The discovery of a series of novel halogenated arylsulfonamides (HAS) as new sigma receptor binding tumor imaging agents is described. Several substituted halogenated sulfonamides have been prepared and characterized. Target compounds were examined for their affinity for sigma(1) and sigma(2) receptor subtypes using guineapig brain membranes and rat liver membranes, respectively. A number of substituted halogenated sulfonamides displayed subnanomolar affinities for sigma(1) sites add low nanomolar affinities for sigma(2) subtype receptors. A limited structure-activity relationship study of this chemical series is discussed. The radioiodination (I-125) of one congener member (4-[I-125]iodo-N-[2-(1'-piperidinyl)ethyl]benzenesulfonamide 4-[I-125]IPBS) was accomplished in high yields. The in vitro competition binding studies of 4-[I-125]IPBS in guinea pig brain membranes with sigma receptor binding ligands confirmed its sigma pharmacology. The rank order of potency was BD1008 [N-[2-(3,4-dichlorophenyl)ethyl]-N-methyl-2-(1-pyrrolidinyl)- ethylamine)> 4-IPBS > haloperidol > (+)-pentazocine > DTG (1,3-di-o-tolylguanidine) > (-)-pentazocine. The inhibition constants (IC50) were 0.70, 1.46, 6.28, 10.4, 87.2, and 152 nM, respectively, and are consistent with labeling of sigma(1) receptors. The tumor imaging potential of 4-[I-125]IPBS was studied in C57 black mice bearing B16 melanoma xenograft. A high tumor uptake of 4-[I-125]IPBS was observed (7.40% ID/g) at 1 h postinjection. The wash out of activity from the tumor was slow at 6 h postinjection (7.22% ID/g). The tumor also had the highest amount of radioactivity (1.54% ID/g) at 24 h postinjection. These results demonstrate that radiohalogenated benzenesulfonamides could be a potentially useful class of compounds in nuclear oncologic scintigraphy.
• John, C.S.; Lim, B. B.; Geyer, B. C., Journal of labelled compounds and radiopharmaceuticals, 1997, vol. 40, p. 637 - 639
  作者：John, C.S.、Lim, B. B.、Geyer, B. C.、Vilner, B. J.、Bowen, W. D.

  DOI：——

  日期：——
• ANTIPATHOGENIC BENZAMIDE COMPOUNDS
  申请人：BURLI Roland W.

  公开号：US20080200465A1

  公开（公告）日：2008-08-21

  The present invention is related to methods of treating viral and protozoan infections in mammals using antipathogenic benzamide compounds having the formula wherein at least one of the R 1 groups is F, Cl, CN or CF 3 and R 2 , R 3 , Y, Z, m, and n are as defined herein.